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PMS74 DEVELOPMENT OF A TOOL TO HELP IN THE EARLY DETECTION OF FIBROMYALGIA (FM) IN GENERAL PRACTICE IN EUROPE
Dias-Barbosa C 1 , Guillemin I 1 , Perrot S 2 , Baron R 3 , Alegre C 4 , Choy E 5 , Cruccu G 6 , Desmeules J 7 , Margaux J 8 , Richards S 9 , Serra E 10 , Spaeth M 11 , Arnould B 1 1 Mapi Values, Lyon, France, 2 Hôpital Hôtel Dieu Paris, Paris, France, 3 Christian-Albrechts Universit, Kiel, Germany, 4 Hospital General Universtiari, Barcelona, Spain, 5 King's College, London, UK, 6 La Sapienza University, Roma, Italy, 7 Geneva University Hospital, Geneva, Switzerland, 8 Erasme Hospital, Brussels, Belgium, 9 Poole Hospital NHS Trust, Poole, UK, 10 North Hospital, Amiens, France, 11 Rheumatology, Gräfelfing, Germany OBJECTIVES: To develop a European screening tool to help primary care physicians (PCPs) identify fibromyalgia (FM) patients in general practice. METHODS: A European multidisciplinary expert group was set up to provide clinical expertise and identify key issues around FM detection. A literature review and focus groups conducted with French (FR), German (DE) and English (UK) clinicians provided an overview of the knowledge in FM and of clinicians' awareness and experience. Psychologists then performed face-to-face exploratory interviews with FM patients (FR, DE and UK, n 29) to understand their attitudes and perceptions of the disease. Based on the findings, items were simultaneously generated in FR, UK and DE. The resulting tool was comprehension tested with FM-diagnosed or -suspected patients (n 3 and n 2 in each country, respectively), and modified based on results. Its acceptability and applicability was then assessed in real-life conditions in general practice. RESULTS: The tool content defined using literature review, health professional and patient input had high consistency regardless of the source from which it was extracted. Factors found that may contribute to the early detection of FM included elements of FM definition, patient characteristics, personal and medical history, quality of life, attitude and personality, associated symptoms and influencing factors. The resulting pilot version of the FM screening tool includes 14 questions assessing patients' pain, fatigue, associated symptoms, impact on patients' everyday life, personal history, and attitudes towards their symptoms. Face validity and feasibility have been confirmed by PCPs and patients when administered in general practice. CONCLUSIONS: In addition to the symptomatic picture, FM detection requires the assessment of multiple factors including patient past history and characteristics, impact of FM on patients' daily life, and situations/factors affecting patients' condition. By capturing each of these factors, the European FM screening tool will help PCPs identify potential FM patients. Quantitative validation of the tool is underway.
PMS75 OAKHQOL, A DISEASE-SPECIFIC HEALTH RELATED QUALITY OF LIFE QUESTIONNAIRE FOR OSTEOARTHRITIS OF THE LOWER LIMB. VALIDITY AND RESPONSIVENESS
Escobar A 1 , González M 1 , Sarasqueta C 2 , Aizpuru F 3 , Herrera C 4 , García-Pérez L 5 1 Hospital de Basurto, Bilbao, Spain, 2 Hospital Donostia, Donostia-San Sebastian, Spain, 3 Hospital de Txagorritxu, Vitoria-Gasteiz, Spain, 4 Hospital Virgen de las Nieves, Granada, Spain, 5 Fundación Canaria de Investigación y Salud, Santa Cruz de Tenerife, Spain OBJECTIVES: Health related quality of life (HRQoL) is an important issue to evaluate outcomes after health interventions. The aim of this study was to study construct validity and responsiveness of the OsteoArthritis of Hip and Knee Quality of Life questionnaire (OAKHQOL), a disease-specific HRQoL for osteoarthritis of the lower limb. METHODS: OAKHQOL is a self administered questionnaire and has 43 items and five dimensions: physical activities (16), pain (4), mental health (13), social support (4) and social functioning (3). There are 3 independent items about relationships, sexual activities and professional life. The score range from 0 (worst) to 100 (best health). Patients were recruited patients from the waiting list to undergo joint replacement. The internal consistency was measured by Cronbach´s alpha (771 patients). The test-retest reliability (413 stable patients who fulfilled the questionnaire two times) was measured by Intraclass correlation coefficient (ICC). The responsiveness was evaluated by means of standardized effect size (SES) and standardized response mean (SRM) six months post surgical replacement. RESULTS: Cronbach´s alpha were all higher than 0.8 but in social activities dimension (0.64). Regarding test-retest reliability the ICCs were higher than 0.75 but in the social activities (0.4) and social support (0.4) dimensions. Finally, responsiveness parameters were: physical dimension (SES 1.26; SRM 0.89); pain (SES 1.37; SRM 0.94); mental health (SES 0.65; SRM 0.56). CONCLUSIONS: These results support the validity and responsiveness of the Spanish version of the OAKHQOL a disease specific HRQoL questionnaire to be used in patients with osteoarthritis of the lower limb and surgical management.
PMS76 PATIENT REPORTED QUALITY-OF-LIFE ISSUES IN MYOTONIC DYSTROPHY TYPE-1 (DM1): A FIRST STEP IN THE DEVELOPMENT OF A DISEASE-SPECIFIC INSTRUMENT
Heatwole C 1 , Chin N 1 , Hilbert J 1 , Holloway R 1 , Johnson N 1 , Pandya S 1 , Moxley R 1 , Quinn C 1 , Thornton C 1 , Vickrey B 2 , Victorson DE 3 1 The University of Rochester Medical Center, Rochester, NY, USA, 2 The Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA, 3 Northwestern University Feinberg School of Medicine/Evanston Northwestern Healthcare, Evanston, IL, USA OBJECTIVES: Development of validated patient-reported outcome (PRO) measures has the potential to positively impact scientific research and patient management. To date, the specific issues and symptoms most relevant to DM1 patients' health related quality-of-life (HRQOL) have not been systematically assessed. Our goal is to identify those aspects of HRQOL that are most important to patients with DM1, a neuromuscular condition with multisystemic organ dysfunction. METHODS: We conducted in-depth individual patient interviews with twenty genetically confirmed, adult, DM1 patients representing varied levels of disability. Each interview focused on identifying the DM1 issues that have the greatest impact on patient HRQOL. Each interview was recorded, transcribed, coded, and analyzed using a qualitative framework technique, triangulation, and three investigator consensus approach. RESULTS: A total of 1175 direct quotes were coded resulting in 223 like themes. These themes were subsequently categorized into 7 subdomains representing physical, mental, and social aspects of DM1 HRQOL. A disease-specific HRQOL conceptual model was created for DM1 representing the most relevant symptomatic and psychosocial issues in this population. Categories in this model included: 1) mobility and ambulation/ fine motor and upper extremity dysfunction; 2) emotional distress; 3) cognitive impairment; 4) social role limitations; 5) social role dissatisfaction; 6) activity impairment; and, 7) DM1-specific symptoms of: sleep disturbance, fatigue, pain/myotonia, gastrointestinal dysfunction, central sensory impairment, and communication difficulties. Difficulty with ambulation was the most frequently mentioned issue by our sample of patients. CONCLU-SIONS: There are multiple themes and symptoms, some previously underrecognized, that play a key role in DM1 patient reported HRQOL. These issues must be carefully examined in order to develop a representative disease-specific conceptual model and PRO measurement tool. The development of such an instrument has the potential to improve DM1 clinical care and maximize the impact and relevance of future DM1 clinical research.
PMS77 FURTHER DEVELOPMENTS OF THE RHEUMATOID ARTHRITIS QUALITY OF LIFE SCALE (RAQOL)
Wilburn J, McKenna SP, Twiss J Galen Research Ltd, Manchester, UK OBJECTIVES: The Rheumatoid Arthritis Quality of Life scale (RAQoL) is the first true QoL measure for RA and is widely used in clinical practice and trials. The scale has good psychometric properties and has been shown to be responsive to changes in disease severity. The objective of the study was to adapt the RAQoL for USA, Mexico,
